Toshiba America Medical Systems Inc. received FDA clearance for two new CT clinical applications, SURECardio Prospective and Variable Helical Pitch (vHP), designed to improve throughput and enhance workflow, while further reducing contrast and radiation dosage.
The applications are available for new Toshiba Aquilion 32- and 64-slice CT systems.
Toshiba’s SURECardio Prospective aims to help reduce patient dose by up to 80 percent during coronary CTA exams by using a helical acquisition technique to provide one continuous image instead of multiple images produced by the current step-and-shoot techniques. SURECardio Prospective is said to automatically detect and adjust to patients with arrhythmia, for quicker, more conclusive exam results.
It is also engineered to automate scan parameters and reconstruction based on the patient’s heart rate. In addition, it speeds exam time and eliminates the need to use additional contrast as with the step-and-shoot method.
October 26, 2026 
